Abstract
Voltage-gated sodium (Na(V)) channels, initially characterized in excitable cells, have been shown to be aberrantly expressed in non-excitable cancer tissues and cells from epithelial origins such as in breast, lung, prostate, colon, and cervix, whereas they are not expressed in cognate non-cancer tissues. Their activity was demonstrated to promote aggressive and invasive potencies of cancer cells, both in vitro and in vivo, whereas their deregulated expression in cancer tissues has been associated with metastatic progression and cancer-related death. This review proposes Na(V) channels as pharmacological targets for anticancer treatments providing opportunities for repurposing existing Na(V)-inhibitors or developing new pharmacological and nutritional interventions.